This suggests that the magnitude of the acute vasodilatory effect of VEGF-A mRNA may lie within a pathophysiologically relevant range, and that basal skin blood flow may have been transiently normalized at VEGF-A mRNA injection sites in men with T2DM following treatment in the present study. This evidence concerns the gene VEGFA and type 2 diabetes mellitus.